Niagen Bioscience, Inc. (NAGE)
Official siteCONSUMER DEFENSIVE • BIOTECHNOLOGY • NASDAQ
Market Cap: $159.19M
Last updated: Nov 17, 2026 at 4:16 PM ET
Niagen Bioscience, Inc. (NAGE) Statistics
Niagen Bioscience (NAGE) has a market cap of $159.19M and an enterprise value of $89.68M. It holds $69.51M more cash than debt, 43.67% of its market cap.
Total Valuation
Enterprise value is 43.67% below the market cap, as cash exceeds debt.
| Market Cap | $159.19M |
|---|---|
| Enterprise Value | $89.68M |
| Latest price (Nov 17, 2026) | $2.04 |
Key Dates
The next earnings report is expected on Mar 2, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 2, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.3x and 1.9x.
| P/E Ratio | 42.9x |
|---|---|
| P/S Ratio | 1.3x |
| Forward P/S | 1.3x |
| P/B Ratio | 1.9x |
| P/TBV Ratio | 2.1x |
| P/OCF Ratio | 32.6x |
Enterprise Valuation
Counting debt and cash, the company is valued at 8.7x EBITDA.
| EV / Earnings | 8.8x |
|---|---|
| EV / Sales | 0.7x |
| EV / EBITDA | 8.7x |
Price Statistics
The stock is down 70.31% over 52 weeks and trades 22.14% below its 50-day average.
| Beta (1Y) | 1.69 |
|---|---|
| 52-Week Change | -70.31% |
| 1-Month Change | -18.40% |
| 3-Month Change | -35.65% |
| 6-Month Change | -44.41% |
| 5-Year Change | -62.36% |
| 10-Year Change | -15.58% |
| Total Return (1Y) | -70.31% |
| Total Return (3Y CAGR) | +12.57% |
| Total Return (5Y CAGR) | -17.97% |
| Return vs SPY (1Y) | -81.82% |
| Max Drawdown (1Y) | -71.45% |
| Max Drawdown (3Y) | -86.05% |
| Sharpe Ratio (1Y) | -2.34 |
| Correlation with SPY (1Y) | 0.45 |
| 50-Day Average | $2.62 |
| 200-Day Average | $3.68 |
| 52-Week Range | $1.97 to $7.12 |
| RSI (14 Days) | 35.6 |
| Average Volume (20 Days) | 579.03K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 5.93x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 5.93x |
|---|---|
| Quick Ratio | 4.71x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is 12.33% over the last 12 months, against a 5-year average of -23.86%.
| Return on Equity (ROE) | 12.33% |
|---|---|
| Return on Assets (ROA) | 9.42% |
| ROE (5Y Average) | -23.86% |
| ROA (5Y Average) | -11.53% |
| ROIC (5Y Average) | 20.06% |
| Asset Turnover | 1.18x |
| Inventory Turnover | 2.15x |
| Receivables Turnover | 15.86x |
| Cash Conversion Cycle | 107 days |
Taxes
Income tax took 7.37% of pretax income over the last 12 months.
| Income Tax (TTM) | $815.00K |
|---|---|
| Effective Tax Rate | 7.37% |
Scores
NAGE has an Altman Z-Score of 4.08, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 4.08 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $122.29M over the last 12 months is down 1.94% from the 12 months before.
| Revenue | $122.29M |
|---|---|
| Revenue Growth (YoY) | -1.94% |
| Gross Profit | $78.10M |
| Operating Income | $4.78M |
| Pretax Income | $11.05M |
| Net Income | $10.24M |
| Reported EPS (TTM) | $0.05 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 76.43% of the $108.69M in total assets.
| Cash and Equivalents | $69.51M |
|---|---|
| Total Debt | $0 |
| Net Cash | $69.51M |
| Net Cash Per Share | $0.88 |
| Working Capital | $83.31M |
| Shareholder Equity | $83.07M |
| Book Value Per Share | $1.05 |
| Tangible Book Value | $77.94M |
| Tangible Book Per Share | $0.98 |
| Total Assets | $108.69M |
| Total Liabilities | $25.62M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | $4.88M |
|---|---|
| FCF Per Share | $0.06 |
| Depreciation and Amortization | $1.07M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 3.90%, against a 5-year average of -10.47%.
| Gross Margin | 63.86% |
|---|---|
| Operating Margin | 3.90% |
| Pretax Margin | 9.04% |
| Net Margin | 8.37% |
| Gross Margin (5Y Average) | 61.56% |
| Operating Margin (5Y Average) | -10.47% |
| Net Margin (5Y Average) | -9.41% |
Growth
Revenue grew 21.56% a year over 3 years.
| Revenue Growth (3Y CAGR) | +21.56% |
|---|---|
| Revenue Growth (5Y CAGR) | +16.91% |
| Book Value Per Share Growth (2Y CAGR) | +54.67% |
| Tangible Book Per Share Growth (2Y CAGR) | +50.19% |
Dividends and Yields
NAGE does not pay a dividend.
| Earnings Yield | 2.33% |
|---|---|
| Buyback Yield | 3.17% |
| Shareholder Yield | 3.17% |
Stock Splits
The last split was a 1-for-3 reverse split on Apr 13, 2016.
| Last Split Date | Apr 13, 2016 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:3 |
Peer Position
Against 7 similar companies, NAGE has the highest P/E.
P/E RatioPeer median 11.1x
P/S RatioPeer median 0.4x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +1.21%
| P/E Ratio | 42.9x vs 11.1x median |
|---|---|
| P/S Ratio | 1.3x vs 0.4x median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -1.94% vs +1.21% median |
Analyst Forecast
Consensus estimates put revenue growth at 2.92% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +2.92% |
|---|---|
| EPS Growth Forecast (1Y CAGR) | -88.07% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About NAGE
What is NAGE's market cap?
Niagen Bioscience has a market cap of $159.19M. Its enterprise value, which adds debt and subtracts cash, is $89.68M.
What is NAGE's P/E ratio?
Niagen Bioscience has a trailing P/E ratio of 42.9x.
How many shares of NAGE are outstanding?
Niagen Bioscience has 79.15M shares outstanding. The count is down 0.79% from a year earlier.
Does NAGE pay a dividend?
No. Niagen Bioscience does not pay a dividend.
How much debt does NAGE have?
Niagen Bioscience has $0 of total debt and $69.51M of cash and equivalents, a net cash position of $69.51M.
NAGE pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors